Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. Strosberg J, et al. Among authors: sierra ml. J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7. J Clin Oncol. 2018. PMID: 29878866 Free PMC article. Clinical Trial.
Safety, tolerability and clinical implementation of 'ready-to-use' 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Manoharan P, Lamarca A, Navalkissoor S, Calero J, Chan PS, Julyan P, Sierra M, Caplin M, Valle J. Manoharan P, et al. ESMO Open. 2020 Mar;5(2):e000650. doi: 10.1136/esmoopen-2019-000650. ESMO Open. 2020. PMID: 32188715 Free PMC article. Clinical Trial.
Scaling Access to Contraception for Youth in Urban Slums: The Challenge Initiative's Systems-Based Multi-Pronged Strategy for Youth-Friendly Cities.
Bose K, Martin K, Walsh K, Malik M, Nyachae P, Sierra ML, Bwire A, Sama D, Kiyola T, Mitchell V, Talla H, Avoce J, Graham K, Sharma M, Varghese D, Ferrand A, Igharo VI, Akila DN. Bose K, et al. Among authors: sierra ml. Front Glob Womens Health. 2021 Oct 1;2:673168. doi: 10.3389/fgwh.2021.673168. eCollection 2021. Front Glob Womens Health. 2021. PMID: 34816226 Free PMC article.
Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH-dependent aldosterone hypersecretion.
Sertedaki A, Markou A, Vlachakis D, Kossida S, Campanac E, Hoffman DA, Sierra ML, Xekouki P, Stratakis CA, Kaltsas G, Piaditis GP, Chrousos GP, Charmandari E. Sertedaki A, et al. Among authors: sierra ml. Clin Endocrinol (Oxf). 2016 Dec;85(6):845-851. doi: 10.1111/cen.13132. Epub 2016 Jul 12. Clin Endocrinol (Oxf). 2016. PMID: 27293068 Free PMC article.
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Sierra ML, Beneton V, Boullay AB, Boyer T, Brewster AG, Donche F, Forest MC, Fouchet MH, Gellibert FJ, Grillot DA, Lambert MH, Laroze A, Le Grumelec C, Linget JM, Montana VG, Nguyen VL, Nicodème E, Patel V, Penfornis A, Pineau O, Pohin D, Potvain F, Poulain G, Ruault CB, Saunders M, Toum J, Xu HE, Xu RX, Pianetti PM. Sierra ML, et al. J Med Chem. 2007 Feb 22;50(4):685-95. doi: 10.1021/jm058056x. Epub 2007 Jan 23. J Med Chem. 2007. PMID: 17243659
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr, Sternbach DD. Sznaidman ML, et al. Among authors: sierra ml. Bioorg Med Chem Lett. 2003 May 5;13(9):1517-21. doi: 10.1016/s0960-894x(03)00207-5. Bioorg Med Chem Lett. 2003. PMID: 12699745
19 results